@article {237,
	title = {Drug Review: Tirzepatide},
	journal = {PTB Reports},
	volume = {9},
	year = {2023},
	month = {November 2023},
	pages = {20-22},
	type = {Drug Review},
	chapter = {20},
	abstract = {<p class="rtejustify">Registrations: Tirzepatide has been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, Saudi Arabia (S.A.). Trade name (USA): MOUNJARO Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: Lilly USA. Regulatory Status: R.X. Mechanism of Action: Tirzepatide is a Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. It is a 39-amino acid-modified peptide containing a C20 fatty diacid component that facilitates albumin binding and increases the halflife. Tirzepatide preferentially binds to and activates GIP and GLP- 1 receptors, hence targeting endogenous GIP and GLP. Tirzepatide increases the first and second phases of insulin secretion and decreases glucagon levels in a glucose-dependent manner. Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes. Indication: Type 2 diabetes mellitus.</p>
},
	doi = {10.5530/PTB.2023.9.3},
	author = {Juman Alsaab}
}
